The authors' own conclusion is the important part: large-scale randomized controlled trials are still needed to establish long-term safety and to determine what, if anything, these agents do to IBD disease activity
(Expert analysis citing 6.7 bpm figure) Eli Lilly press release: TRIUMPH-4 Phase 3 topline results
Efficacy and Safety of Retatrutide, a Novel GLP-1, GIP, and Glucagon Receptor Agonist for Obesity Treatment: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Abdrabou Abouelmagd A
Statistical analysis performed with one-way ANOVA followed by Tukey HSD post-test
Tackle Emotional Eating GLP-1s blunt food cravings but when theyre gone, emotional triggers return
Extra caution is warranted for people with: Gastroparesis or delayed gastric emptying GLP-1 medications significantly delay gastric emptying and are generally not recommended in severe gastroparesis